In-silico Analyses of Drug-induced Liver Malignant Tumor Signals Based on Molecular Initiating Events and Mutagenicity Using FDA Adverse Event Reporting System Database

Abstract

Liver Malignant Tumors (LMT) have been reported as adverse drug reactions in clinical settings. However, it is difficult to conduct comprehensive in vivo studies to evaluate factors of drug-induced LMT. Therefore, we attempted to define signals of LMT-inducing drugs by multivariate analysis of FAERS and to construct a prediction model for LMT signal detection using mutagenicity, and agonist/antagonist activities against nuclear receptors and stress response pathways. We consider examining the model to estimate various information of Adverse Outcome Pathways related to drug-induced LMT.